Bern joined OMERS in 2016 and as Managing Director, Life Sciences is focused on origination, evaluation and negotiation of royalty monetization transactions and investments across the capital structure in commercial-stage biopharma and medical device companies.

Before joining OMERS, Bern worked for more than ten years at DRI Capital, a drug royalty investment firm. Bern also worked previously at Novo Nordisk (Canada), where he was responsible for sales and marketing analytics for the biopharmaceuticals portfolio.

Bern received a PhD in neurophysiology and molecular biology from Queen’s University in Kingston, where he held an NSERC Scholarship.  He received an MBA from the University of Toronto, where he held an Ontario Graduate Scholarship.